Gane P J, Dean P M
De Novo Pharmaceuticals Ltd., Cambridge, UK.
Curr Opin Struct Biol. 2000 Aug;10(4):401-4. doi: 10.1016/s0959-440x(00)00105-6.
Two approaches to structure-based drug design, that is, the docking of known compounds into a target protein and molecular assembly in situ, are seen to be merging technologies. The need for structural information about drug-protein complexes is now fundamental for drug discovery.
基于结构的药物设计有两种方法，即已知化合物与目标蛋白对接以及原位分子组装，这两种方法正逐渐融合为一项技术。如今，对于药物-蛋白质复合物结构信息的需求已成为药物研发的基础。
Zotero 插件